Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2004-09-08 Regulatory Filings
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys Obtains License on Crucell Human Cell Line
Regulatory Filings Classification · 95% confidence The document is a 'Corporate-news announcement' dated September 8, 2004, detailing a non-exclusive license agreement between MorphoSys AG and Crucell N.V. regarding cell line technology. This type of announcement, which details a specific business development, partnership, or technology agreement, does not fit neatly into the defined categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). It is a general corporate update. Since it is not a report itself but a news release about a business event, and it doesn't specifically relate to management changes (MANG), director dealings (DIRS), capital changes (CAP/SHA), or dividends (DIV), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements or corporate news releases that don't fit elsewhere.
2004-09-08 English
MorphoSys Announces Inclusion into TecDAX Index
Regulatory Filings Classification · 100% confidence The document is a short corporate news announcement dated September 6, 2004, detailing MorphoSys AG's inclusion into the TecDAX index. It is not a comprehensive financial report (like 10-K or IR), nor is it a specific filing related to dividends, management changes, or director dealings. It is a general, time-sensitive announcement of a corporate event (index inclusion) released via a news distribution service (DGAP). Since it doesn't fit into the highly specific categories like ER, CAP, or DIRS, and it is a general regulatory/market announcement, the most appropriate fallback category is Regulatory Filings (RNS), as it serves as a general market disclosure.
2004-09-06 English
MorphoSys Announces Change in Management Board
Board/Management Information Classification · 100% confidence The document is explicitly titled 'MorphoSys Announces Change in Management Board' and details the departure of the Chief Scientific Officer (Dr. Thomas von Rüden) and subsequent reassignment of responsibilities among the remaining board members, along with promotions of other personnel. This content directly aligns with the definition of 'Board/Management Information' (Code: MANG), which covers announcements of changes in the company's board of directors or senior management.
2004-09-03 English
Centocor Extends License to MorphoSys Therapeutic Antibody
Regulatory Filings Classification · 100% confidence The document is a 'Corporate-news announcement' detailing a specific business event: Centocor exercising an option to extend a license agreement with MorphoSys and receiving a license payment. This is a specific operational update concerning partnerships and technology licensing, not a general financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). It is a specific corporate action announcement. Since there is no specific category for 'License Agreement Update' or 'Partnership News', and it is not a standard regulatory filing like a major shareholding change (MRQ) or director dealing (DIRS), the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a general corporate news release distributed via a news service (DGAP). Given the nature of the content (a press release about a business deal), RNS is the best fit among the provided options, although it is not a formal SEC filing.
2004-08-25 English
MorphoSys and Boehringer Ingelheim Start New Antibody Program
M&A Activity Classification · 99% confidence The document is a 'Corporate-news announcement' dated August 16, 2004, detailing a new antibody development program between MorphoSys and Boehringer Ingelheim. It discusses a collaboration agreement, milestone payments, and the exercise of an option. This type of announcement, which communicates a specific business event (like a partnership or development update) but is not a formal regulatory filing like a 10-K, ER, or IR, fits best under the general category for corporate news or regulatory updates that don't have a more specific code. Since it is a news announcement about a business development, and not a formal financial report, it is classified as a Regulatory Filing (RNS) as the general fallback for corporate news announcements that don't fit other specific categories (like M&A, Capital Change, or Dividend Notice). It is not an Earnings Release (ER) or Interim Report (IR) as it focuses on R&D collaboration, not financial results.
2004-08-16 English
MorphoSys Reports Six Months 2004 Results... (Correction)
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement dated July 29, 2004, reporting financial results for the 'Six Months 2004' period (first half of the year). It details revenues, expenses, EBITDA, net loss, and cash position for the first half of 2004, and also raises full-year guidance. This content structure—a summary of period-specific financial performance for a period shorter than a year—is characteristic of an Interim/Quarterly Report (IR). Although it is an announcement, it contains the core financial highlights and explanatory remarks, making it more substantial than a simple 'Report Publication Announcement' (RPA). The mention of a conference call suggests it is the primary release of the period results. H1 2004
2004-07-29 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.